MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 563401 | Name: Tranilast sodium

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tranilast is an inhibitor of the production of interleukin-6 in endothelial cells. It acts by reducing collagen synthesis in fibroblasts and inhibiting growth of neurofibroma cells.

Chemical Structure

Tranilast sodium
Tranilast sodium
CAS#Tranilast sodium

Theoretical Analysis

MedKoo Cat#: 563401

Name: Tranilast sodium

CAS#: Tranilast sodium

Chemical Formula: C18H16NNaO5

Exact Mass: 327.1107

Molecular Weight: 349.32

Elemental Analysis: C, 61.89; H, 4.62; N, 4.01; Na, 6.58; O, 22.90

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
53902-12-8 70806-55-2 (free acid) Tranilast sodium
Synonym
Tranilast; Rizaben; SB-252218; SB 252218; SB252218; Tranilast sodium;
IUPAC/Chemical Name
sodium (E)-2-[[3-(3,4-Dimethoxyphenyl)-1-oxo-2-propenyl]amino]benzoate
InChi Key
KZGHWWBBHZLTTA-VRTOBVRTSA-M
InChi Code
InChI=1S/C18H17NO5.Na/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22;/h3-11H,1-2H3,(H,19,20)(H,21,22);/q;+1/p-1/b10-8+;
SMILES Code
O=C(O[Na])C1=CC=CC=C1NC(/C=C/C2=CC=C(OC)C(OC)=C2)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 349.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Pascart T, Richette P. Investigational drugs for hyperuricemia, an update on recent developments. Expert Opin Investig Drugs. 2018 May;27(5):437-444. doi: 10.1080/13543784.2018.1471133. Epub 2018 May 9. Review. PubMed PMID: 29718730. 2: Abe S, Iyer PG, Oda I, Kanai N, Saito Y. Approaches for stricture prevention after esophageal endoscopic resection. Gastrointest Endosc. 2017 Nov;86(5):779-791. doi: 10.1016/j.gie.2017.06.025. Epub 2017 Jul 14. Review. PubMed PMID: 28713066. 3: Zhan W, Lu F. Activated macrophages as key mediators of capsule formation on adipose constructs in tissue engineering chamber models. Cell Biol Int. 2017 Apr;41(4):354-360. doi: 10.1002/cbin.10731. Epub 2017 Mar 7. Review. PubMed PMID: 28102640. 4: Bock KW. From dioxin toxicity to putative physiologic functions of the human Ah receptor in homeostasis of stem/progenitor cells. Biochem Pharmacol. 2017 Jan 1;123:1-7. doi: 10.1016/j.bcp.2016.06.015. Epub 2016 Jun 25. Review. PubMed PMID: 27349986. 5: Yoneta K, Fujimoto N, Teramura K, Takayama S, Tanaka T. Disseminated granulomatous skin lesions associated with myelodysplastic syndrome treated successfully with tranilast: a case report and review of the literature. Eur J Dermatol. 2016 Aug 1;26(4):398-400. doi: 10.1684/ejd.2016.2812. Review. PubMed PMID: 27229541. 6: Jain D, Singhal S. Esophageal Stricture Prevention after Endoscopic Submucosal Dissection. Clin Endosc. 2016 May;49(3):241-56. doi: 10.5946/ce.2015.099. Epub 2016 Mar 7. Review. PubMed PMID: 26949124; PubMed Central PMCID: PMC4895939. 7: Wang S, Li B, Li C, Cui W, Miao L. Potential Renoprotective Agents through Inhibiting CTGF/CCN2 in Diabetic Nephropathy. J Diabetes Res. 2015;2015:962383. doi: 10.1155/2015/962383. Epub 2015 Sep 2. Review. PubMed PMID: 26421309; PubMed Central PMCID: PMC4572424. 8: Rajda C, Majláth Z, Pukoli D, Vécsei L. Kynurenines and Multiple Sclerosis: The Dialogue between the Immune System and the Central Nervous System. Int J Mol Sci. 2015 Aug 6;16(8):18270-82. doi: 10.3390/ijms160818270. Review. PubMed PMID: 26287161; PubMed Central PMCID: PMC4581244. 9: Shahid H, Singh JA. Investigational drugs for hyperuricemia. Expert Opin Investig Drugs. 2015;24(8):1013-30. doi: 10.1517/13543784.2015.1051617. Epub 2015 Jun 14. Review. PubMed PMID: 26073200. 10: Darakhshan S, Pour AB. Tranilast: a review of its therapeutic applications. Pharmacol Res. 2015 Jan;91:15-28. doi: 10.1016/j.phrs.2014.10.009. Epub 2014 Nov 10. Review. PubMed PMID: 25447595. 11: Ciacci C, Bucci C, Zingone F, Iovino P, Amato M. Buccal localization of Crohn's disease with long-term infliximab therapy: a case report. J Med Case Rep. 2014 Nov 30;8:397. doi: 10.1186/1752-1947-8-397. Review. PubMed PMID: 25433368; PubMed Central PMCID: PMC4265509. 12: Ammendola M, Leporini C, Marech I, Gadaleta CD, Scognamillo G, Sacco R, Sammarco G, De Sarro G, Russo E, Ranieri G. Targeting mast cells tryptase in tumor microenvironment: a potential antiangiogenetic strategy. Biomed Res Int. 2014;2014:154702. doi: 10.1155/2014/154702. Epub 2014 Sep 11. Review. PubMed PMID: 25295247; PubMed Central PMCID: PMC4177740. 13: Guerra E, Byrne RA, Kastrati A. Pharmacological inhibition of coronary restenosis: systemic and local approaches. Expert Opin Pharmacother. 2014 Oct;15(15):2155-71. doi: 10.1517/14656566.2014.948844. Epub 2014 Aug 22. Review. PubMed PMID: 25145263. 14: Arno AI, Gauglitz GG, Barret JP, Jeschke MG. Up-to-date approach to manage keloids and hypertrophic scars: a useful guide. Burns. 2014 Nov;40(7):1255-66. doi: 10.1016/j.burns.2014.02.011. Epub 2014 Apr 24. Review. PubMed PMID: 24767715; PubMed Central PMCID: PMC4186912. 15: Chuang PY, Menon MC, He JC. Molecular targets for treatment of kidney fibrosis. J Mol Med (Berl). 2013 May;91(5):549-59. doi: 10.1007/s00109-012-0983-z. Epub 2012 Nov 22. Review. PubMed PMID: 23179685; PubMed Central PMCID: PMC3594378. 16: Hessen M, Akpek EK. Ocular graft-versus-host disease. Curr Opin Allergy Clin Immunol. 2012 Oct;12(5):540-7. doi: 10.1097/ACI.0b013e328357b4b9. Review. PubMed PMID: 22892710. 17: Rogosnitzky M, Danks R, Kardash E. Therapeutic potential of tranilast, an anti-allergy drug, in proliferative disorders. Anticancer Res. 2012 Jul;32(7):2471-8. Review. PubMed PMID: 22753703. 18: Ogawa R. [Treatment of surgical site infection and hypertrophic scars]. Kyobu Geka. 2012 May;65(5):409-17. Review. Japanese. PubMed PMID: 22569501. 19: Prud'homme GJ. Cancer stem cells and novel targets for antitumor strategies. Curr Pharm Des. 2012;18(19):2838-49. Review. PubMed PMID: 22390767. 20: Tomino Y. Mechanisms and interventions in peritoneal fibrosis. Clin Exp Nephrol. 2012 Feb;16(1):109-14. doi: 10.1007/s10157-011-0533-y. Epub 2011 Sep 21. Review. PubMed PMID: 21935614.